Vac­cine sales are ex­pect­ed to fade af­ter a Q1 pop at As­traZeneca, but a slate of suc­cess­ful fran­chis­es buoys fore­cast

All the pis­tons dri­ving rev­enue growth were pump­ing dur­ing As­traZeneca’s Q1, with Alex­ion con­tribut­ing to strong per­for­mance in the Big Phar­ma’s swelling on­col­o­gy busi­ness. But there’s one new con­trib­u­tor that As­traZeneca CEO Pas­cal So­ri­ot says is head­ed for a fall.

Their Covid-19 vac­cine fran­chise — ham­mered ear­ly by some fleet­ing con­cerns about a rare side ef­fect — reg­is­tered more than a bil­lion dol­lars in sales in Q1, with Evusheld con­tribut­ing an ad­di­tion­al $469 mil­lion. But even as Evusheld sales are ex­pect­ed to grow, the vac­cine sales are ex­pect­ed to di­min­ish as the world has flipped from a scarci­ty of pan­dem­ic vac­cines to a glut.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER